UPDATE - Lexicon Pharmaceuticals to Host Second Quarter 2018 Financial Results Conference Call and Webcast on July 30, 2018
July 23 2018 - 4:46PM
Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), will release its
second quarter 2018 financial results on Monday, July 30, 2018
before market opens. Management will conduct a conference call and
live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss
the financial results and to provide a business update.
Dial-in InformationU.S. Dial-in
Number: (888) 645-5785International Dial-in Number:
(970) 300-1531Conference ID: 8776903
Replay InformationU.S. Dial-in
Number: (855) 859-2056Replay International Dial-in
Number: (404) 537-3406Conference ID: 8776903
The dial-in replay will be available for 7 days
following the call. An audio webcast will be available online in
the investor relations section of the company website at
www.lexpharma.com/investors, with a webcast replay accessible for
14 days after the call.
About Lexicon
Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical
company that is applying a unique approach to gene science based on
Nobel Prize-winning technology to discover and develop precise
medicines for patients with serious, chronic conditions. Through
its Genome5000™ program, Lexicon scientists have studied the role
and function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. In addition to its first commercial product,
XERMELO® (telotristat ethyl), Lexicon has a
pipeline of promising drug candidates in clinical and pre-clinical
development in diabetes and metabolism and neuropathic pain. For
additional information please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s growth and
future operating results, discovery, development and
commercialization of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management’s current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including those relating to Lexicon’s ability to meet its capital
requirements, successfully commercialize XERMELO (telotristat
ethyl), successfully obtain regulatory approvals of sotagliflozin
and successfully conduct preclinical and clinical development and
obtain necessary regulatory approvals of LX2761, LX9211 and its
other potential drug candidates on its anticipated timelines,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon’s actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Information identifying
such important factors is contained under “Risk Factors” in
Lexicon’s annual report on Form 10-K for the year ended December
31, 2017, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or
revise any such forward-looking statements, whether as a result of
new information, future events or otherwise.
For Investor Inquiries:
Kimberly Lee, D.O.Head of Investor Relations and
Corporate StrategyLexicon Pharmaceuticals(281)
863-3383klee@lexpharma.com
For Media Inquiries:
Chas SchultzExecutive Director, Corporate
Communications and Patient AdvocacyLexicon Pharmaceuticals(281)
863-3421cschultz@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024